Verve Gross Profit from 2010 to 2025

VERV Stock

USD 5.55 0.01 0.18%

Verve Therapeutics Gross Profit yearly trend continues to be fairly stable with very little volatility. Gross Profit is likely to outpace its year average in 2025. Gross Profit is the profit Verve Therapeutics makes after deducting the costs associated with making and selling its products, or the costs associated with providing its services. View All Fundamentals

Gross Profit

First Reported

2010-12-31

Previous Quarter

32.3 M

Current Value

33.9 M

Quarterly Volatility

11.6 M

Credit Downgrade

Yuan Drop

Covid

Check Verve Therapeutics financial statements over time to gain insight into future company performance. You can evaluate financial statements to find patterns among Verve Therapeutics' main balance sheet or income statement drivers, such as Net Interest Income of 30.2 M, Interest Income of 8.3 M or Depreciation And Amortization of 3.3 M, as well as many indicators such as Price To Sales Ratio of 13.96, Dividend Yield of 0.0 or PTB Ratio of 1.01. Verve financial statements analysis is a perfect complement when working with Verve Therapeutics Valuation or Volatility modules.

Check out the analysis of Verve Therapeutics Correlation against competitors.

For more information on how to buy Verve Stock please use our How to Invest in Verve Therapeutics guide.

Latest Verve Therapeutics' Gross Profit Growth Pattern

Below is the plot of the Gross Profit of Verve Therapeutics over the last few years. Gross profit is a required income statement account that reflects total revenue of Verve Therapeutics minus its cost of goods sold. It is profit before Verve Therapeutics operating expenses, interest payments and taxes. Gross profit is also known as gross margin. It is the profit a company makes after deducting the costs associated with making and selling its products, or the costs associated with providing its services. Verve Therapeutics' Gross Profit historical data analysis aims to capture in quantitative terms the overall pattern of either growth or decline in Verve Therapeutics' overall financial position and show how it may be relating to other accounts over time.

View

Last Reported 9.48 M

10 Years Trend

Slightly volatile

Compare to Others All Fundamentals

Gross Profit

Timeline

Verve Gross Profit Regression Statistics

	Arithmetic Mean	3,878,038
	Coefficient Of Variation	300.20
	Mean Deviation	7,618,686
	Median	(106,000)
	Standard Deviation	11,641,877
	Sample Variance	135.5T
	Range	38.7M
	R-Value	0.56
	Mean Square Error	99.6T
	R-Squared	0.31
	Significance	0.02
	Slope	1,370,631
	Total Sum of Squares	2033T

Verve Gross Profit History

	2025	33.9 M
	2024	32.3 M
	2023	6.3 M
	2022	-4.8 M
	2021	-3.4 M
	2020	-1.3 M

Other Fundumenentals of Verve Therapeutics

Gross Profit Margin

Verve Therapeutics Gross Profit component correlations

	Total Assets	Total Stockholder Equity	Net Tangible Assets	Current Deferred Revenue	Net Debt	Retained Earnings	Accounts Payable	Short Term Investments	Total Liab	Net Invested Capital	Total Current Assets	Capital Stock	Net Working Capital	Short Term Debt	Common Stock	Property Plant Equipment	Net Receivables	Capital Surpluse	Deferred Long Term Liab
Total Assets		0.99	0.96	0.65	-0.87	-0.89	0.67	0.99	0.78	0.99	1.0	0.98	1.0	0.88	0.98	0.94	0.36	0.92	-0.43
Total Stockholder Equity	0.99		0.96	0.62	-0.9	-0.86	0.73	0.99	0.7	1.0	0.99	0.98	0.99	0.88	0.98	0.92	0.34	0.89	-0.4
Net Tangible Assets	0.96	0.96		0.49	-0.92	-0.95	0.68	0.95	0.72	0.96	0.96	0.96	0.96	0.84	0.96	0.98	0.32	0.9	-0.65
Current Deferred Revenue	0.65	0.62	0.49		-0.52	-0.48	0.33	0.58	0.63	0.62	0.63	0.56	0.63	0.57	0.56	0.55	0.6	0.63	0.01
Net Debt	-0.87	-0.9	-0.92	-0.52		0.87	-0.87	-0.85	-0.51	-0.9	-0.88	-0.91	-0.88	-0.65	-0.91	-0.86	-0.53	-0.8	0.55
Retained Earnings	-0.89	-0.86	-0.95	-0.48	0.87		-0.59	-0.85	-0.79	-0.86	-0.89	-0.92	-0.88	-0.71	-0.92	-0.97	-0.45	-0.92	0.77
Accounts Payable	0.67	0.73	0.68	0.33	-0.87	-0.59		0.67	0.18	0.73	0.69	0.73	0.69	0.35	0.73	0.54	0.57	0.46	-0.27
Short Term Investments	0.99	0.99	0.95	0.58	-0.85	-0.85	0.67		0.74	0.99	0.99	0.97	0.99	0.89	0.97	0.92	0.28	0.87	-0.41
Total Liab	0.78	0.7	0.72	0.63	-0.51	-0.79	0.18	0.74		0.7	0.77	0.75	0.77	0.69	0.75	0.82	0.37	0.84	-0.45
Net Invested Capital	0.99	1.0	0.96	0.62	-0.9	-0.86	0.73	0.99	0.7		0.99	0.98	0.99	0.88	0.98	0.92	0.34	0.89	-0.4
Total Current Assets	1.0	0.99	0.96	0.63	-0.88	-0.89	0.69	0.99	0.77	0.99		0.98	1.0	0.87	0.98	0.93	0.36	0.91	-0.43
Capital Stock	0.98	0.98	0.96	0.56	-0.91	-0.92	0.73	0.97	0.75	0.98	0.98		0.98	0.81	1.0	0.93	0.4	0.93	-0.48
Net Working Capital	1.0	0.99	0.96	0.63	-0.88	-0.88	0.69	0.99	0.77	0.99	1.0	0.98		0.87	0.98	0.93	0.37	0.9	-0.42
Short Term Debt	0.88	0.88	0.84	0.57	-0.65	-0.71	0.35	0.89	0.69	0.88	0.87	0.81	0.87		0.81	0.84	-0.05	0.84	-0.32
Common Stock	0.98	0.98	0.96	0.56	-0.91	-0.92	0.73	0.97	0.75	0.98	0.98	1.0	0.98	0.81		0.93	0.4	0.93	-0.48
Property Plant Equipment	0.94	0.92	0.98	0.55	-0.86	-0.97	0.54	0.92	0.82	0.92	0.93	0.93	0.93	0.84	0.93		0.34	0.94	-0.69
Net Receivables	0.36	0.34	0.32	0.6	-0.53	-0.45	0.57	0.28	0.37	0.34	0.36	0.4	0.37	-0.05	0.4	0.34		0.32	-0.22
Capital Surpluse	0.92	0.89	0.9	0.63	-0.8	-0.92	0.46	0.87	0.84	0.89	0.91	0.93	0.9	0.84	0.93	0.94	0.32		-0.52
Deferred Long Term Liab	-0.43	-0.4	-0.65	0.01	0.55	0.77	-0.27	-0.41	-0.45	-0.4	-0.43	-0.48	-0.42	-0.32	-0.48	-0.69	-0.22	-0.52

Click cells to compare fundamentals

About Verve Therapeutics Financial Statements

Verve Therapeutics investors use historical fundamental indicators, such as Verve Therapeutics' Gross Profit, to determine how well the company is positioned to perform in the future. Understanding over-time patterns can help investors decide on long-term investments in Verve Therapeutics. Please read more on our technical analysis and fundamental analysis pages.

	Last Reported	Projected for Next Year
Gross Profit	32.3 M	33.9 M
Gross Profit Margin	0.48	0.51

Thematic Opportunities

Explore Investment Opportunities

Build portfolios using Macroaxis predefined set of investing ideas. Many of Macroaxis investing ideas can easily outperform a given market. Ideas can also be optimized per your risk profile before portfolio origination is invoked. Macroaxis thematic optimization helps investors identify companies most likely to benefit from changes or shifts in various micro-economic or local macro-level trends. Originating optimal thematic portfolios involves aligning investors' personal views, ideas, and beliefs with their actual investments.

Explore Investing Ideas

Additional Tools for Verve Stock Analysis

When running Verve Therapeutics' price analysis, check to measure Verve Therapeutics' market volatility, profitability, liquidity, solvency, efficiency, growth potential, financial leverage, and other vital indicators. We have many different tools that can be utilized to determine how healthy Verve Therapeutics is operating at the current time. Most of Verve Therapeutics' value examination focuses on studying past and present price action to predict the probability of Verve Therapeutics' future price movements. You can analyze the entity against its peers and the financial market as a whole to determine factors that move Verve Therapeutics' price. Additionally, you may evaluate how the addition of Verve Therapeutics to your portfolios can decrease your overall portfolio volatility.

Macroaxis helps investors of all levels and skills to maximize the upside of all their holdings and minimize the risk associated with market volatility, economic swings, and company-specific events. View terms and conditions

Feedback Blog

Made with optimal in San Francisco

2024 Macroaxis LLC